Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.55% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-11
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.55%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 1.74%.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.55%, a 1.11% increase from fiscal 2024.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.50%, a 6.44% decline from fiscal 2023.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.81%, a 21.16% increase from fiscal 2022.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.97%, a 128.16% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.55% 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 4.55% 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 4.55% 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 4.55% 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 4.50% 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 4.31% 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | 4.81% 10-K · filed 2025-02-27 | |||
| 2022-12-31 | 3.97% 10-K · filed 2024-03-28 | |||
| 2022-09-30 | 4.14% 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | 1.74% 10-K · filed 2023-03-30 | |||
| 2021-09-30 | 1.74% 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 1.74% 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 1.74% 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 1.33% 10-K · filed 2022-03-31 | |||
| 2020-09-30 | 1.33% 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | 1.33% 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | 3.02% 10-K · filed 2021-03-19 | |||
| 2019-09-30 | 2.65% 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | 2.65% 10-Q · filed 2020-08-14 | |||
| 2018-12-31 | 3.02% 10-K · filed 2020-03-25 | |||
| 2018-09-30 | 3.02% 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |